IL-15 and T cell stemness in T cell-based cancer immunotherapy

Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T cell transfer immunotherapy in clinical tri...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2015-12, Vol.75 (24), p.5187-5193
Main Authors: Pilipow, Karolina, Roberto, Alessandra, Roederer, Mario, Waldmann, Thomas A., Mavilio, Domenico, Lugli, Enrico
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. Interleukin-15 (IL-15), a potent immunostimulatory cytokine, both potentiates host T and NK-cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity with potential use in adoptive T-cell transfer protocols. IL-15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8 + memory T cells. The recent advances in the knowledge of IL-15-dependent regulation of T-cell responses, gene expression and metabolic adaptation have important implications for the use of IL-15 in T cell-based immunotherapy of cancer.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-15-1498